The newly developed compound, dubbed HypoxyStat, has shown remarkable efficacy in preclinical studies. In a recent experiment conducted on mice with Leigh Syndrome—a genetic disorder that significantly hampers mitochondrial function—treatment with HypoxyStat resulted in astonishing improvements. Mice that received this innovative therapy experienced a life expectancy that tripled, coupled with notable reversals in debilitating symptoms, including severe brain damage and muscle weakness. In a field where options have traditionally been limited, these findings suggest that this drug may not only extend life but potentially enhance the quality of life for sufferers of mitochondrial diseases.

One of the key obstacles in treating mitochondrial diseases lies in the dysfunctional energy production processes of cells. In Leigh Syndrome specifically, cells inadequately harness oxygen to generate energy, leading to toxic levels of unused oxygen accumulating in tissues. This excess oxygen can wreak havoc, killing cells and exacerbating symptoms. Traditionally, researchers explored the potential of low-oxygen environments as a therapeutic measure, revealing that conditions akin to those found at altitudes of 4,500 meters (approximately 14,764 feet) could alleviate symptoms by preventing this toxic accumulation of oxygen. However, relocating patients to high altitudes is impractical, limiting the effectiveness of this approach.

Dr. Isha Jain, a prominent Gladstone Investigator and senior author of the study published in the esteemed journal Cell, emphasized the need for alternative methods to achieve similar therapeutic effects without subjecting patients to the rigors of altitude. Recognizing the limitations of environmental manipulation, Jain’s team set out to explore molecular solutions. Their unique approach centered on hemoglobin, the protein responsible for oxygen transport in the blood. The hypothesis was simple yet counterintuitive: by increasing hemoglobin’s affinity for oxygen, it would deliver less of it to tissues, effectively mimicking the effects of low-oxygen environments.

The collaboration with Maze Therapeutics, a biotechnology company based in South San Francisco, enabled the team to identify the chemical compound already known to increase hemoglobin’s oxygen-binding affinity and subsequently named HypoxyStat. This drug had originally been designed for treating sickle cell anemia, but its potential for application in mitochondrial diseases like Leigh Syndrome became evident through rigorous testing. HypoxyStat not only limited excess oxygen delivery to tissues but also showed promise in halting and even reversing the progression of the disease.

What stood out in the research was not only the drug’s preventative capabilities but also its therapeutic potential once symptoms had manifest. Mice that began receiving HypoxyStat later in life, when major symptoms had already developed, experienced notable reversals in their conditions. For example, severe brain lesions, muscle weakness, and behavioral impairments significantly improved with consistent administration of the drug. This significant finding opens up new avenues for therapeutic intervention, suggesting that even once significant damage has occurred, recovery may still be possible.

The implications of this research extend beyond mitochondrial diseases. Jain notes the potential versatility of HypoxyStat; its principles may apply to other conditions that could benefit from reduced oxygen levels, including a variety of neurological and cardiovascular disorders. Furthermore, the research could catalyze the development of new pharmacological strategies aimed at manipulating oxygen transport in more than one direction—some drugs may one day be designed to enhance tissue oxygen delivery when needed, significantly improving patient outcomes in various medical scenarios.

The field is on the cusp of a potential revolution in how we approach not just mitochondria-based disorders but broader applications of hypoxia-based therapies. The notion of gas-based therapies—consolidated into powerful, targeted drugs—represents a paradigm shift in treating not only rare diseases but potentially common health issues that remain difficult to address with conventional methods. As the research continues, the scientific community eagerly anticipates the next steps in this promising journey.

For the innovative minds at the Gladstone Institutes, this is not just a theoretical exercise but a matter of life and death for many patients suffering from terminal conditions. They are actively pursuing second-generation versions of HypoxyStat to fast-track clinical testing. Considering the potential of these developments, the hope is that patients grappling with mitochondrial diseases could soon have access to a safe, controlled intervention that dramatically transforms their prognosis.

As research unfolds and clinical trials begin, the scientific community remains vigilant about the risks and challenges of introducing such novel therapies. Ethical considerations surrounding patient safety, long-term efficacy, and implications for broader healthcare practices must always be prioritized. Still, this trailblazing work offers significant hope for individuals and families affected by mitochondrial diseases—a change that could redefine treatment paradigms for generations to come.

In conclusion, the work conducted by Jain and colleagues serves as a remarkable testament to the power of innovative research in transforming the landscape of medicine. By rediscovering and repurposing existing compounds, scientists are not only addressing immediate health needs but are also paving the way for future breakthroughs in our understanding of how oxygen impacts cellular function on a mechanical level. What lies ahead is a tantalizing possibility that medical science can adapt and evolve, ultimately unlocking solutions for even the most daunting health challenges.

Subject of Research: Mitochondrial diseases and therapeutic interventions
Article Title: HypoxyStat, A Small Molecule Form of Hypoxia Therapy that Increases Hemoglobin-Oxygen Affinity
News Publication Date: February 17, 2025
Web References: Gladstone Institutes, Cell Journal
References: Jain, I., et al. (2025). HypoxyStat, a Small Molecule Form of Hypoxia Therapy That Increases Hemoglobin-Oxygen Affinity. Cell. DOI: 10.1016/j.cell.2025.01.029
Image Credits: Photo: Michael Short/Gladstone Institutes

Keywords: Mitochondrial diseases, HypoxyStat, Hemoglobin, Leigh syndrome, Oxygen therapy, Biomedical research, Gladstone Institutes, Drug development

In recent years, a range of mitochondrial base editors (BEs) emerged, including DddA-derived cytosine base editors (DdCBEs) and TALE-linked deaminases (TALEDs). Our own laboratory introduced a new type of mitochondrial base editor, abbreviated mitoBE, capable of cytosine-to-thymine (C-to-T) and adenine-to-guanine (A-to-G) conversions in the mitochondrial genome. These constructs combine a double-stranded or single-stranded DNA deaminase with a DNA nickase, harnessing the potential of transcription activator-like effectors (TALEs) that are customized to bind specific sequences in mtDNA. The original version of mitoBEs, described previously, showed minimal off-target editing, primarily because the TALE design confers strong strand specificity. Nonetheless, the fervent push for generating mouse models to replicate the precise mutations implicated in human mitochondrial disorders called for an even higher level of accuracy and efficiency, particularly when microinjecting these tools as RNA into zygotes.

The next-generation variant, termed mitoBEs v2, arose from the thorough redesign of adenine and cytosine deaminases to mitigate unwanted off-target edits. When expressed in cells, the original versions of these mitochondrial base editors were shown to cause occasional undesired edits in the mitochondrial genome and, more significantly, in transcripts, because certain cytosine and adenine deaminases can inadvertently bind and deaminate RNA. This risk becomes more pronounced when the editors are delivered in the form of mRNA, which yields higher expression levels and correspondingly higher on-target editing but also riskier interactions with off-target substrates. By strategically mutating and screening key residues within TadA, a bacterial adenine deaminase commonly used for adenine base editing, the new version of mitoABE included the substitution V28F in TadA8e-V106W, leading to substantially improved specificity and reduced RNA off-target edits. In parallel, our team explored a library of cytosine deaminases for an alternative to APOBEC1—the widely used but often promiscuous deaminase—ultimately selecting CBE6d, a TadA-derived cytosine deaminase that delivered a higher degree of efficiency and a narrower editing window.

Having validated mitoBEs v2 in cultured cells, we systematically screened 70 pathogenic point mutations in the mouse mitochondrial genome that mirror known human mutations. Among these, we found 68 to be editable by mitoBEs v2, indicating that the modified editors maintain broad applicability for disease modeling. The editing efficiency often exceeded 10%, and in some loci, including mt-Rnr1 A978G, mt-TrnV G1029A, mt-Atp6 T8576C, mt-Atp6 T8591C, mt-Nd5 T12499C, and mt-Nd5 A12784G, we observed rates of up to 20–25% in cultured neuroblastoma cells. While such cell-line testing provides only an initial screening for the feasibility of each target site, it also reveals the interplay between TALE binding, deaminase activity, and the architecture of the target sequence in shaping how effectively any given site can be mutated.

The next challenge was to translate this high efficiency to live animals, where editing has to happen at the zygote stage so that every cell in the adult mouse carries the mtDNA change, making it possible to recapitulate human disease phenotypes. We chose two specific positions for in vivo proof-of-concept studies: mt-Atp6 T8591C, corresponding to the human m.T9191C mutation implicated in Leigh syndrome, and mt-Nd5 A12784G, mirroring the human m.A13379G mutation implicated in LHON. When we delivered mRNA or circRNA encoding the new mitoBEs v2 into one-cell mouse embryos, the editing efficiencies reached unprecedented levels. Notably, circRNA-encoded mitoBEs v2 proved more effective than mRNA-encoded versions, often doubling the mutation rates. In some embryos, we attained editing efficiency upward of 60% at T8591C or 62% at A12784G when analyzed at the blastocyst stage. Extending this success to live offspring, many F0 mice carried mutation loads of 40–50% or even up to 82% at their respective loci, underscoring the ability of mitoBEs v2 to create highly heteroplasmic or near-homoplasmic conditions.

This level of editing in F0 mice is particularly important for studying mitochondrial disorders because disease phenotypes often manifest only when the proportion of mutated mtDNA surpasses a threshold. In LHON, for instance, the typical threshold is around 60% for the mutant mtDNA to induce the visual impairments commonly observed in patients, though lower loads can sometimes be sufficient. By generating mice in which the majority of their mtDNA is mutated, we produce more faithful analogs of human disease states, facilitating a clearer understanding of pathological mechanisms and the development of treatments. Importantly, we verified the specificity of these edits. Whole-genome sequencing revealed no significant off-target editing within the nuclear genome at relevant sequencing depths, and a thorough survey of potential off-target sites, including computational predictions with TALENoffer, showed the background to be effectively clean. Even in the mitochondrial genome, where the original version of mitoCBEs occasionally introduced off-target conversions, the new cytosine deaminase variant CBE6d displayed minimal detectable bystander or off-target edits.

One of the most intriguing discoveries about these newly engineered mice was the extent to which the mutations were stably propagated across various somatic tissues and over time. By sampling 26 tissues at 2 months of age in two different F0 mice, we saw that editing levels remained relatively stable in many tissues. Some variations were detected, which could be due to the interplay between environmental factors, tissue-specific energetic demands, and potential selective pressures on certain mtDNA variants. Indeed, such tissue-specific segregation is part of the broader story of the mitochondrial genetic bottleneck, wherein different subpopulations of mtDNA can get amplified or suppressed depending on energetic or developmental constraints.

The question of heritability was addressed by mating female mice carrying the edited mtDNA with wild-type males. mtDNA is well known to be maternally inherited in mammals. We observed that mutation loads fluctuated in F1 and F2 generations, sometimes increasing, sometimes decreasing, a classic manifestation of the mitochondrial bottleneck effect. Remarkably, some F1 offspring attained 100% mutation load at the A12784G site, showcasing the potential to generate fully homoplasmic lines within just one generation. In contrast, the T8591C variants seemed detrimental to embryonic development or gamete maturation, as illustrated by lower birth rates in those lines and a gradual diminution of the T8591C mutation over subsequent generations. By the F2 or F3 generation, T8591C either was substantially reduced or disappeared in most offspring, pointing to a powerful selective force that eliminates highly deleterious mtDNA variants.

These lineage-tracking observations in mice are emblematic of the broader phenomenon experienced by human carriers of pathogenic mtDNA. Some families are known to spontaneously lose or reduce detrimental variants over generations, presumably because these variants compromise oocyte or embryo viability. Conversely, other variants, even if pathogenic, can persist or expand under certain circumstances. The ability to control and quantify these effects in a laboratory mouse population is an invaluable asset for dissecting exactly how mitochondrial heteroplasmy shifts occur, what molecular signals lead to selection for or against certain mtDNA haplotypes, and how to potentially intervene in disease scenarios.

Phenotypic characterization of the F0 mice revealed disease-relevant symptoms that mirror clinical data in humans. Mice with high editing levels at T8591C in mt-Atp6 had significantly reduced heart rates and a notably diminished left ventricular ejection fraction as assessed by echocardiography. Leigh syndrome is often associated with severe cardiovascular and neurological abnormalities. The phenotypic data in these mice strengthen the link between that particular point mutation and the observed phenotype, consistent with human clinical observations that T9191C can lead to Leigh syndrome with pronounced cardiac manifestations. Similarly, the mice carrying the A12784G mutation in mt-Nd5 displayed impaired visual function evidenced by electroretinography. Under dark-adapted conditions, both a-wave and b-wave responses were suppressed in these animals, and under light-adaptation conditions, the b-wave responses were notably depressed. LHON in humans is characterized by central vision loss, optic atrophy, and deficits in the photoreceptor signals, which aligns with these findings. By recapitulating such phenotypes, these new mouse lines represent crucial platforms for future interventions, drug testing, and mechanistic analyses of mitochondrial diseases.

Despite these accomplishments, a challenge remains in achieving truly single-base alterations without introducing secondary edits in the adjacent window. Because TALE-based editors typically incorporate a small window in which deamination can occur, multiple bases within that window can be converted if the sequence context permits. While the presence of bystander mutations is tolerable in certain therapeutic contexts, disease modeling demands the highest precision to unambiguously link genotype to phenotype. In the present study, we addressed this by shifting the TALE-binding sites in the mt-Nd5 A12784G system, effectively narrowing the potential editing window so that only the base at position 12784 is selectively edited. Indeed, some screening in cell lines identified pairs of TALE monomers that yield cleaner edits, and embryo injections of these improved pairs gave rise to F0 mice whose only edit was at the target site. Phenotypic tests using electroretinography on these single-mutation mice confirmed that even in the absence of neighboring bystander mutations, the A12784G change was sufficient to cause LHON-like visual defects. Therefore, rational design of TALE binding, coupled with the improved catalytic specificity of deaminases, can yield nearly perfect single-base mitochondrial edits.

The success of mitoBEs v2 in generating robust mouse models of disease points the way to further possibilities in therapeutic development. Gene therapy approaches using adeno-associated virus or lipid-based nanoparticle systems could, in principle, deliver these editors to adult tissues. However, the inefficiency of delivering proteins or RNAs specifically to mitochondria in vivo remains a formidable obstacle. The impetus to solve such challenges is growing, given that more than 90 disease-related point mutations in human mtDNA have been identified. Of these, around 85 are theoretically addressable by some form of base editor that converts A-to-G or C-to-T. Although the present study focuses on using mitoBEs v2 to produce heritable changes in mouse zygotes, one can envision analogous methods, refined delivery vehicles, or direct in vivo injections that eventually correct pathogenic variants in patients.

Moreover, the principle of generating clean backgrounds for disease modeling fosters confidence that the observed phenotypes reflect the intended single mutation or cluster of mutations, rather than confounding off-target effects in the nuclear genome. As we scaled from single-blastocyst analyses to whole-litter screens and then entire F0 and F1 cohorts, we saw no evidence of spurious large-scale nuclear edits or integration events, which historically have bedeviled certain gene-editing tools. This is crucial not only for basic science but also for any translational endeavor where specificity is key to meeting regulatory standards for safety.

Another intriguing aspect of the new mitochondrially targeted editors is their compatibility with circular RNA (circRNA). CircRNA vectors are more stable than linear mRNAs, conferring prolonged expression. This was reflected in the heightened editing efficiencies in mouse embryos injected with circRNA constructs, where sustained editor expression presumably facilitated more comprehensive editing of mtDNA. The successful translation of circRNA in mitochondria-targeted editing underscores the broader potential of circular RNA technologies across various domains of gene therapy, from disease modeling in preclinical species to future therapeutic interventions in humans.

In sum, the research on mitoBEs v2 ushers in a new era of mitochondrial disease modeling, bridging the gap between theoretical constructs of disease-causing mutations and fully realized mouse lines that recapitulate human syndromes. The capacity to achieve editing efficiencies of up to 82% in F0 mice, combined with the successful demonstration of maternal inheritance and phenotypic manifestations closely matching known human conditions, is a definitive testament to the power of these refined genome-editing tools. These mouse models have already yielded insights into how pathogenic mtDNA influences embryonic and tissue-specific viability, how the mutation load can shift dramatically from mother to offspring, and how single-point changes in critical mitochondrial proteins directly provoke the cardinal features of Leigh syndrome or LHON. For the research community, the newly minted mouse lines that mimic other mitochondrial disorders—be it through tRNA mutations or protein-coding gene alterations—offer an expansive toolkit to elucidate unknown mechanisms and test novel therapeutic strategies.

The quest for single-base editing in mitochondrial DNA, once limited by a dearth of tools and hampered by the intricacy of delivering effectors to mitochondria, is now coming to fruition. The lessons learned from the iterative optimization of mitoBEs v2—especially the efforts to minimize RNA off-target edits and reduce promiscuous deaminase activity—will undoubtedly inform future developments, perhaps enabling the next generation of mitochondrially targeted editors to be even safer and more precise. Ultimately, the synergy between robust mitochondrial base editing and advanced in vivo delivery systems could herald genuine clinical interventions for a wide spectrum of mitochondrial disorders, enabling the possibility that familial burdens associated with debilitating mutations can be alleviated by precise reprogramming of the mitochondrial genome. Far from being a mere technical feat, these breakthroughs embody a promising leap toward conquering inherited metabolic conditions that have long stood as insurmountable clinical challenges.

Subject of Research: Mitochondrial genome base editing to create mouse models of human mitochondrial diseases

Article Title : Precise modelling of mitochondrial diseases using optimized mitoBEs

News Publication Date : 22 January 2025

Keywords : Mitochondrial diseases, base editing, mitoBEs v2, genome editing, animal models, TALE-fused deaminases, off-target effects, maternal inheritance, disease phenotypes, Leigh syndrome, LHON, circRNA technology